ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo
ScripAstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change
ScripGilead Sciences’ TROP2-directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) has a strong chance of cornering most of the market for first-line advanced or metastatic triple-negative
ScripMerck & Co. and Daiichi Sankyo had hoped the HER3-targeting antibody drug conjugate (ADC) patritumab deruxtecan would be the first to reach the market under a massive deal spanning three ADCs and